SpheNoPain: Sphenopalatine Ganglion Block and Pain Management in Neurosurgery

Sponsor
University Hospital of Ferrara (Other)
Overall Status
Recruiting
CT.gov ID
NCT05136625
Collaborator
(none)
84
1
2
40.9
2.1

Study Details

Study Description

Brief Summary

Post craniotomy pain is defined as headache developed up to 7 days from a craniotomy, not otherwise explained. A moderate to severe pain affects from 60 to 84% of patients.

Sphenopalatine ganglion block has been successfully used in patients with chronic or acute headache, facial pain and for transsphenoidal pituitary and endoscopic sinus surgeries.

There are evidences that sphenopalatine ganglion block reduces vegetative responses to skull pin closure.

This study aim to investigate feasibility and efficacy of sphenopalatine ganglion block in reducing pain after a neurosurgical supratentorial craniotomy.

Condition or Disease Intervention/Treatment Phase
  • Drug: Sphenopalatine ganglion block
  • Drug: Standard Preparation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
Sphenopalatine Ganglion Block and Pain Management in Neurosurgery
Actual Study Start Date :
Feb 1, 2021
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control

Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine)

Drug: Standard Preparation
Troncular scalp blockade. Local site infiltration

Experimental: Treatment

Troncular scalp blockade (Levobupivacaine 7,5%) Local site infiltration (Mepivacaine) Transnasal sphenopalatine ganglion block (Levobupivacaine 7,5%)

Drug: Sphenopalatine ganglion block
A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described

Drug: Standard Preparation
Troncular scalp blockade. Local site infiltration

Outcome Measures

Primary Outcome Measures

  1. Numerical Rating Scale [Immediately post-op]

    From 0 (no pain) to 10 (worst pain ever)

  2. Numerical Rating Scale [1° days post-op]

    From 0 (no pain) to 10 (worst pain ever)

  3. Numerical Rating Scale [2° days post-op]

    From 0 (no pain) to 10 (worst pain ever)

  4. Numerical Rating Scale [3° days post-op]

    From 0 (no pain) to 10 (worst pain ever)

  5. Numerical Rating Scale [4° days post-op]

    From 0 (no pain) to 10 (worst pain ever)

  6. Numerical Rating Scale [30° days post-op]

    From 0 (no pain) to 10 (worst pain ever)

  7. Numerical Rating Scale [60° days post-op]

    From 0 (no pain) to 10 (worst pain ever)

  8. Numerical Rating Scale [180° days post-op]

    From 0 (no pain) to 10 (worst pain ever)

  9. Visual Analogic Scale [Immediately post-op]

    From 0 (no pain) to 10 (worst pain ever)

  10. Visual Analogic Scale [1° day post-op]

    From 0 (no pain) to 10 (worst pain ever) on a straight line

  11. Visual Analogic Scale [2° day post-op]

    From 0 (no pain) to 10 (worst pain ever) on a straight line

  12. Visual Analogic Scale [3° day post-op]

    From 0 (no pain) to 10 (worst pain ever) on a straight line

  13. Visual Analogic Scale [4° day post-op]

    From 0 (no pain) to 10 (worst pain ever) on a straight line

  14. Visual Analogic Scale [30° day post-op]

    From 0 (no pain) to 10 (worst pain ever) on a straight line

  15. Visual Analogic Scale [60° day post-op]

    From 0 (no pain) to 10 (worst pain ever) on a straight line

  16. Visual Analogic Scale [180° day post-op]

    From 0 (no pain) to 10 (worst pain ever) on a straight line

  17. Pain Assessment IN Advanced Dementia [Immediately post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

  18. Pain Assessment IN Advanced Dementia [1° day post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

  19. Pain Assessment IN Advanced Dementia [2° day post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

  20. Pain Assessment IN Advanced Dementia [3° day post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

  21. Pain Assessment IN Advanced Dementia [4° day post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

  22. Pain Assessment IN Advanced Dementia [30° day post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

  23. Pain Assessment IN Advanced Dementia [60° day post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

  24. Pain Assessment IN Advanced Dementia [180° day post-op]

    From 0 (no signs of pain) to 10 (Extreme pain)

Secondary Outcome Measures

  1. Adverse effect [Immediately post-op, 1°-2°-3°-4°-30°-60°180° days post-op]

    Bitter taste, nose bleeding, throat discomfort

  2. Vegetative response (Heart rate) [1-5-10 min from skull pin closure. 1-5-10 min from skin incision]

    Heart rate in beat per minute

  3. Vegetative response (Arterial pressure) [1-5-10 min from skull pin closure. 1-5-10 min from skin incision]

    Mean arterial pressure in mmHg

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • supratentorial craniotomy
Exclusion Criteria:
  • prior craniofacial pain syndrome

  • drug assumption: pain-killers (chronic), antiepileptic

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sant'Anna Hospital Ferrara Emilia Romagna Italy 44124

Sponsors and Collaborators

  • University Hospital of Ferrara

Investigators

  • Study Chair: Pasquale De Bonis, MD PhD, Università degli Studi di Ferrara

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital of Ferrara
ClinicalTrials.gov Identifier:
NCT05136625
Other Study ID Numbers:
  • 553/2021/Sper/AOUFe
First Posted:
Nov 29, 2021
Last Update Posted:
Nov 29, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital of Ferrara
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 29, 2021